AlphAIAlphAI — Financial news for AI agents
MarketBeatAPR 12 min read$GANX

HC Wainwright Has Positive Estimate for GANX Q1 Earnings

HC Wainwright has revised its Q1 2026 earnings estimates for Gain Therapeutics (NASDAQ:GANX), now projecting a smaller loss per share of ($0.13), an improvement from their previous forecast of ($0.15). The firm maintains a "Buy" rating and an $8.00 price target for the stock. This update follows Gain Therapeutics' recent earnings report where they surpassed consensus estimates by reporting ($0.11) EPS against a projected ($0.14).

Original reporting
MarketBeat · MarketBeat
Published Apr 1, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 11:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright Has Positive Estimate for GANX Q1 Earnings — source image
Source · MarketBeat
Decision brief

The 30-second read

$GANXBullishMed
01

Why it matters

The revision and earnings beat suggest strengthening fundamentals, potentially leading to stock appreciation.

02

Market read

The news is relevant for investors interested in biotech stocks, particularly GANX, and may influence short-term trading decisions.

03

What to watch

Potential regulatory hurdles or clinical trial results could adversely affect GANX's stock despite positive earnings estimates.

Relevance 6/10Timing: Immediate, as the news is recent and relevant for current trading sessions.

Background

HC Wainwright's positive revision reflects improved outlook for Gain Therapeutics following recent earnings beat.

Company-level read

Ticker impact

$GANXBullishHigh confidence
Context

The positive earnings estimate revision and surpassing consensus earnings suggest a potential bullish trend.

Expected impact

Moderate upward price movement expected in the short to medium term.

Evidence & confidence

The revision of earnings estimates from HC Wainwright, combined with the recent earnings beat, indicates improved investor sentiment and potential for stock appreciation. The 'Buy' rating and $8.00 target support a bullish outlook.

Market effects

Sector

The life sciences sector may experience slight positive sentiment due to improved earnings outlooks within biotech firms.

Regional

Limited regional impact; primarily relevant to US-based biotech stocks.

Global

Minimal; specific to the biotech industry and individual company performance.

Counterpoint

What could challenge this read

Some investors may view the optimistic estimates as overly speculative, especially if broader market conditions deteriorate.

Key entities

  • Company
    Gain Therapeutics

    Biotech company focused on developing therapeutics for neurodegenerative diseases.

  • Analyst Firm
    HC Wainwright

    Investment bank providing equity research and earnings estimates.

Read at source← All news

Related articles

OCT 5
$GANXMedAI 8/10

BTIG reiterates Buy on Gain Therapeutics stock on trial data

BTIG reiterated a Buy rating and $5.00 price target for Gain Therapeutics (GANX), citing positive Phase 1b trial data for GT-02287 in Parkinson’s disease. The stock has a Strong Buy consensus, with targets ranging from $5 to $8. The company plans to submit a Phase 2 protocol to the FDA and initiate the study in Q1 2027. GANX reported strong financial health, with a current ratio of 4.36. H.C. Wainwright also reiterated a Buy rating with an $8.00 target.

investing.com2 min
OCT 1
$GANXMedAI 8/10

Gain Therapeutics reports stable motor scores in Parkinson’s trial

Gain Therapeutics (GANX) reported stable motor function scores in Parkinson’s patients after 12 months of rexaceract treatment in a Phase 1b trial, with no significant safety issues. The company plans to submit a Phase 2 study protocol to the FDA soon. Participants showed stabilization in MDS-UPDRS motor scores, with no clinically meaningful progression of symptoms. Both high and low baseline GluSph groups benefited, and adverse events decreased over time.

investing.com2 min
OCT 1
$GANXMedAI 8/10

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Gain Therapeutics (GANX) presented Phase 1b data showing that 12-month administration of rexaceract stabilized MDS-UPDRS motor scores in Parkinson’s disease patients, with no disease progression observed. The company plans to submit a Phase 2 study protocol to the FDA and initiate the trial in Q1 2027. Rexaceract demonstrated a favorable safety profile and potential disease-modifying activity.

globenewswire.com2 min
OCT 1
$GANXMedAI 8/10

Gain Therapeutics reports 12-month rexaceract data showing stable MDS-UPDRS and plans Phase 2 start in Q1 2027

Gain Therapeutics presented 12-month data showing stable MDS-UPDRS motor scores in patients treated with rexaceract, suggesting potential disease-modifying effects. The company plans to start a Phase 2 trial in Q1 2027, with protocol submission to the FDA expected soon. As of August 31, 2026, 12 of 13 evaluable patients completed 12 months of treatment, with one remaining to complete in November 2026. Rexaceract was generally well tolerated.

tradingview.com1 min
OCT 1
$GANXMedAI 9/10

Gain Therapeutics, Inc. issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement…

Gain Therapeutics, Inc. (GANX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 1, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. The post

SEC EDGAR 8-K2 min